Korea’s Drug Pricing and Incentive Reform: What You Need to Know
Korea, the world’s 13th-largest pharma market, is rolling out its biggest reform to pharma pricing in a generation, slashing what it pays for generics and using the savings to get…
Founded in November 2010, P&K Skin Research Center was established to provide scientific and systematic technical support and information according to various customers’ demands about clinical tests for developing new ingredients as well as functional cosmetics and quasi-drugs. P&K Skin Research Center started through a strategic alliance with Daebong LS Ltd, which is the only company manufacturing and selling pharmaceutical and cosmetic and healthy functional food ingredients, and Chung-ang University Research Center for Medical Scieces, which was the first research center to own a general hospital in Korea.
P&K Skin Research Center is equipped with facilities that meet not only the KFDA and EU guidelines but also US standards. Through analyzing all functional stroma and protocol from physical through to chemical inspection techniques for pharmaceutical ingredients, and through 30 years’ history of Daebong LS, we clinically test efficacy of general cosmetic and functional ingredients and cosmetics in accordance with KFDA, EU and US guidelines. Through these scientific evaluations, we are trying to provide scientific technical support and information for consumer satisfaction about products directly applied to the skin.
We do our utmost to ensure scientific validity, objectivity and also transparency for efficacy and functionality evaluation with Daebong LS, which has abundant clinical experiences at manufacturing and analysis, especially for pharmaceutical and cosmetic ingredients, and our experts include a dermatologist of a university hospital who has various clinical test experiences.
Contact details:
City B/D 2F, 118-2 Heukseok-dong, Dongjak-gu, Seoul 156-860 Korea
+82 2 6295 1501~3
Korea, the world’s 13th-largest pharma market, is rolling out its biggest reform to pharma pricing in a generation, slashing what it pays for generics and using the savings to get…
The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather…
Korea’s position as a clinical trials hub did not happen overnight. The country has treated clinical development as a matter of deliberate government policy for the better part of two…
We have set a goal that by 2027, more than 740,000 Korean patients will be benefiting from our treatments Christoph Hamann, General Manager of Merck Healthcare Korea, highlights strong momentum…
Building stronger bridges between Korean biotech companies and global capital will be critical to unlocking the ecosystem’s full potential Chang Woo Lee, CEO of CUROGEN, discusses translating academic science into…
Biosimilars have already saved health systems billions of dollars, yet adoption still varies wildly by geography. With a wave of major biologics losing patent protection this decade, the market opportunity…
Korea’s real strength right now is active, innovative discovery research, and that expertise, along with international networking, keeps improving Jungwon Woo, MedPacto CEO, discusses translating innovative cancer research into clinical…
I believe we can position Korea as a true global leader in biohealth innovation Lee Hyung Hoon, Vice Minister at Korea’s Ministry of Health and Welfare, outlines his vision for…
We are actively evolving into a nation that discovers innovative drug candidates Korea’s clinical trial sector has spent the past two decades transforming itself from a fast follower into one…
Even a truly great medicine delivers limited value if patients cannot actually benefit from it Jeong Tae Kim, General Manager of Daiichi Sankyo Korea, has spent 18 years with the…
What I want, more than anything, is to introduce this modality to patients as quickly and as properly as possible Jaejin Cho, CEO of CellinCells, explains how the company’s proprietary…
Donghoon Lee outlines SK Biopharmaceuticals’ transformation into a global neuroscience player. He discusses the growth of its epilepsy profile, selective expansion into Parkinson’s disease and oncology, and acquisitions. Lee also…
See our Cookie Privacy Policy Here
